CD28 and neoplasm: To determine if the PD1-CD28 CSR enhances the fitness of TRuC-T cells, we subjected them to an in vitro tumor rechallenge assay with MSTOMSLN-PD-L1 tumor cells at a low effector-to-target ratio, followed by a rechallenge every 96 h.